A network flow approach to predict drug targets from microarray data, disease genes and interactome network - case study on prostate cancer.

Shih-Heng Yeh, Hsiang-Yuan Yeh, Von-Wun Soo
{"title":"A network flow approach to predict drug targets from microarray data, disease genes and interactome network - case study on prostate cancer.","authors":"Shih-Heng Yeh, Hsiang-Yuan Yeh, Von-Wun Soo","doi":"10.1186/2043-9113-2-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Systematic approach for drug discovery is an emerging discipline in systems biology research area. It aims at integrating interaction data and experimental data to elucidate diseases and also raises new issues in drug discovery for cancer treatment. However, drug target discovery is still at a trial-and-error experimental stage and it is a challenging task to develop a prediction model that can systematically detect possible drug targets to deal with complex diseases.</p><p><strong>Methods: </strong>We integrate gene expression, disease genes and interaction networks to identify the effective drug targets which have a strong influence on disease genes using network flow approach. In the experiments, we adopt the microarray dataset containing 62 prostate cancer samples and 41 normal samples, 108 known prostate cancer genes and 322 approved drug targets treated in human extracted from DrugBank database to be candidate proteins as our test data. Using our method, we prioritize the candidate proteins and validate them to the known prostate cancer drug targets.</p><p><strong>Results: </strong>We successfully identify potential drug targets which are strongly related to the well known drugs for prostate cancer treatment and also discover more potential drug targets which raise the attention to biologists at present. We denote that it is hard to discover drug targets based only on differential expression changes due to the fact that those genes used to be drug targets may not always have significant expression changes. Comparing to previous methods that depend on the network topology attributes, they turn out that the genes having potential as drug targets are weakly correlated to critical points in a network. In comparison with previous methods, our results have highest mean average precision and also rank the position of the truly drug targets higher. It thereby verifies the effectiveness of our method.</p><p><strong>Conclusions: </strong>Our method does not know the real ideal routes in the disease network but it tries to find the feasible flow to give a strong influence to the disease genes through possible paths. We successfully formulate the identification of drug target prediction as a maximum flow problem on biological networks and discover potential drug targets in an accurate manner.</p>","PeriodicalId":73663,"journal":{"name":"Journal of clinical bioinformatics","volume":"2 1","pages":"1"},"PeriodicalIF":0.0000,"publicationDate":"2012-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3285036/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical bioinformatics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/2043-9113-2-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Systematic approach for drug discovery is an emerging discipline in systems biology research area. It aims at integrating interaction data and experimental data to elucidate diseases and also raises new issues in drug discovery for cancer treatment. However, drug target discovery is still at a trial-and-error experimental stage and it is a challenging task to develop a prediction model that can systematically detect possible drug targets to deal with complex diseases.

Methods: We integrate gene expression, disease genes and interaction networks to identify the effective drug targets which have a strong influence on disease genes using network flow approach. In the experiments, we adopt the microarray dataset containing 62 prostate cancer samples and 41 normal samples, 108 known prostate cancer genes and 322 approved drug targets treated in human extracted from DrugBank database to be candidate proteins as our test data. Using our method, we prioritize the candidate proteins and validate them to the known prostate cancer drug targets.

Results: We successfully identify potential drug targets which are strongly related to the well known drugs for prostate cancer treatment and also discover more potential drug targets which raise the attention to biologists at present. We denote that it is hard to discover drug targets based only on differential expression changes due to the fact that those genes used to be drug targets may not always have significant expression changes. Comparing to previous methods that depend on the network topology attributes, they turn out that the genes having potential as drug targets are weakly correlated to critical points in a network. In comparison with previous methods, our results have highest mean average precision and also rank the position of the truly drug targets higher. It thereby verifies the effectiveness of our method.

Conclusions: Our method does not know the real ideal routes in the disease network but it tries to find the feasible flow to give a strong influence to the disease genes through possible paths. We successfully formulate the identification of drug target prediction as a maximum flow problem on biological networks and discover potential drug targets in an accurate manner.

Abstract Image

Abstract Image

Abstract Image

从芯片数据、疾病基因和交互组网络预测药物靶点的网络流方法--前列腺癌案例研究。
背景:药物发现的系统方法是系统生物学研究领域的一门新兴学科。它旨在整合相互作用数据和实验数据以阐明疾病,同时也为癌症治疗的药物发现提出了新的课题。然而,药物靶点的发现仍处于试错实验阶段,如何开发一种预测模型,系统地检测可能的药物靶点,以应对复杂的疾病,是一项极具挑战性的任务:方法:我们整合了基因表达、疾病基因和相互作用网络,采用网络流方法识别出对疾病基因影响较大的有效药物靶点。在实验中,我们采用了包含 62 个前列腺癌样本和 41 个正常样本的微阵列数据集、108 个已知的前列腺癌基因以及从 DrugBank 数据库中提取的 322 个已批准的治疗人类的药物靶点作为候选蛋白作为测试数据。利用我们的方法,我们对候选蛋白质进行了优先排序,并将它们与已知的前列腺癌药物靶点进行了验证:结果:我们成功地发现了与已知前列腺癌治疗药物密切相关的潜在药物靶点,同时也发现了更多目前引起生物学家关注的潜在药物靶点。我们发现,仅根据差异表达变化很难发现药物靶点,因为那些被认为是药物靶点的基因并不总是有显著的表达变化。与以往依赖网络拓扑属性的方法相比,我们发现有可能成为药物靶点的基因与网络中的临界点相关性很弱。与之前的方法相比,我们的结果具有最高的平均精度,而且真正的药物靶点的位置排序也更靠前。这也验证了我们方法的有效性:我们的方法不知道疾病网络中真正的理想路径,但它试图找到可行的流程,通过可能的路径对疾病基因产生强烈的影响。我们成功地将药物靶点预测识别表述为生物网络中的最大流问题,并准确地发现了潜在的药物靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信